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ABSTRACT 
 
Background and Aim: the long time interval for a trial of thioupurine therapy and the potential side 
effects in spite of the proven efficacy, do not encourage their use as early therapeutic option in 
Crohn’s Disease (CD). The development of tests predictive of   responsiveness represents a major 
attempt in the clinical management of CD patients. Azathioprine (AZA) is able to induce apoptosis 
of T cells; therefore we analyzed the “in vitro” thiopurine-induced T cells apoptosis in a group of 
CD patients with known response to a previous treatment with AZA. Methods:  peripheral CD4+ T 
cells from 16 CD patients were stimulated with CD3/28 mAbs in the presence or absence of AZA 
or 6-MP or 6-thioguanine; apoptosis was assessed using Annexin V staining. Results: Apoptosis 
stimulation index (% of apoptotic cells in the presence of thiopurine /  % of apoptotic cells in their 
absence) was significantly lower in non responder   when compared to responder patients (1.46 
(0.97-1.8) vs. 2.19 (1.58-2.65) median (range), respectively; p=0.002 by Mann Whitney test). 
Conclusions: evaluation of apoptosis stimulation index of peripheral CD4+T cell induced by AZA 
might represent a parameter useful for a proper selection of CD patients candidate to thiopurine 
treatment. 
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INTRODUCTION 
 
Azathioprine (AZA) and mercaptopurine (MP) are established immunomodulatory drugs 
successfully used as chemotherapeutic in inflammatory bowel disease (IBD) (1).  AZA and MP 
have proven efficacy in induction of remission in active CD and the response increases after 17 
weeks, suggesting there is a minimum length of time for trial of thioupurine therapy (2). These 
drugs have a proven steroid-sparing effect (2) and efficacy in CD patients with perianal disease (3). 
AZA and MP are more effective than placebo for maintenance of remission in CD (4) and more 
recently showed efficacy in preventing CD recurrence after surgery, especially in high risk patients 
(5). In IBD patients treated with thiopurines, up to 20% had to discontinue treatment due to adverse 
events related to dose-dependent pharmacologically explainable events and dose-independent, 
hypersensitivity reactions (6). Therefore, although AZA and MP show proven efficacy, the 
relatively long term treatment required to obtain a full pharmacological effect together with possible 
adverse reactions, do not encourage the use of thioupurines as an early therapeutic option. The 
possibility to predict their efficacy in each single patient might encourage a more aggressive 
strategy with an early use of these immunomodulatory drugs rather then a conventional therapeutic 
approach (7, 8). The monitoring of 6-thioguanine nucleotides (6-TGNs) and 6-
methylmercaptopurine (6-MMP) metabolites has been proposed for the evaluation of clinical 
efficacy (9), although a recent meta-analysis of such studies shows a relatively low sensitivity in 
predicting clinical response (10). Recently, it has been demonstrated that the immunosuppressive 
effects of azathioprine is related to its ability to induce apoptosis (11) of T cells which, in CD, is 
defective (12). Consequently, more recently, the evaluation of 6-thioguanosine triphosphate levels 
directly responsible for the proapoptotic effect and its precursor 6-thioguanoside diphosphate has 
been proposed for the prediction of azathioprine responsiveness in IBD patients (13). However, the 
monitoring of   metabolites implies the assumption of the drug for an adequate length of time and, 
therefore, the exposure to the risk of adverse effects.  
Aim of the present study was to analyse the “in vitro” thiopurine-induced peripheral T cells 
apoptosis in a group of CD patients with known response to a previous treatment with azathioprine. 
The effect of thiopurine on T cell apoptosis “in vitro”   was studied and the results analyzed 
according to the response to the previous treatment.  
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METHODS 
Patients  
 
Adult CD patients were retrospectively selected on the basis of clinical records of all CD patients 
under regular follow up at the GI Unit of the University of Tor Vergata of Rome (Italy). Inclusion 
criteria were adult CD patients currently in follow up previously treated with AZA with clinical 
indication and dosage according to current guidelines (14). Patients were excluded if reliable data 
on clinical response could not be ascertained, or if a stable AZA therapy over a period of at least 6 
months could not be recorded. AZA responsiveness was defined as steroid-free clinical remission 
and/or at least 50% fistulas closure for 1 month.   
Blood sampling  
Heparinised peripheral blood samples (20cc) were obtained from 16 compliant CD patients during a 
scheduled follow up visit. At the time of blood collection, clinical characteristics of patients (CD 
localization, disease activity, drug treatments, and time length of thiopurine-free therapy) were 
recorded. Blood samples were processed according to the below reported protocol. Investigators 
were blind to the patients clinical data during all the experimental procedure.   
Peripheral blood mononuclear cells (PBMC) were isolated using Ficoll-Paque (Pharmacia 
Biotech, Upsala, Sweden) density gradient.  Purified CD4+T cells were obtained from PBMC by 
immunomagnetic negative selection using CD4+ T cell isolation Kit II (Miltenyi Biotec, 
Auburn,CA, USA) The resulting (unbound) CD4+T cell population contained greater than 96% 
CD4+ cells as assessed by flow cytometric analysis.    
Cell cultures 
CD4+T cells (1 x 106) were resuspended in 1 ml of complete medium (RPMI 1640 supplemented 
with 2mM L-glutamine, 100U/ml of penicillin, 50 g/ml of streptomycin, 25 g/ml of gentamycin 
and 10% heat-inactivated FCS) and cultured for 4-5 days in   24-well plates in a humidified 5% 
CO2 incubator in the presence of recombinant IL-2 (20 U/ml; Roche Diagnostic, Indianapolis, IN, 
USA).  Cells were cultured either in the absence of any stimulus or in the presence   of plate-bound 
anti-CD3 Ab (0.04 g/ml; BD Biosciences Pharmingen, San Diego, CA, USA) and soluble anti-
CD28 (1 g/ml; BD Biosciences Pharmingen), in the presence or absence of AZA, 6-MP or 6-
thioguanine (6-TG) (all from Sigma-Aldrich) used at 5 µM concentration, for 4-5 days. In few 
experiments, in additional cultures, cells were incubated with AZA 10M. At the end of the culture 
period, supernatants were collected and stored at -20°C for further analysis and cells were collected 
for apoptosis evaluation.  Apoptosis was assessed using Annexin V staining (BD Biosciences 
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Pharmingen, San Diego, CA, USA) and analyzed by FACScan cytofluorimeter and expressed as % 
apoptotic cells. The degree of apoptosis induction was expressed as apoptosis stimulation index 
using the following formula: % apoptosis in culture in the presence of AZA/% of apoptosis in the 
absence of AZA 
Cytokine measurement  
The amount of IFN- in cell supernatants was measured by ELISA using commercially available 
kits (BD Biosciences Pharmingen, San Diego, California, USA) following manufacturer’s 
instructions. 
Statistical evaluation 
Mann-Whitney and Wilcoxon test were used as appropriated 
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RESULTS 
Patients  
The clinical characteristics of patients included   in the study, as well as the indication for AZA 
treatment and response evaluation   are summarized in Table 1.  All patients received AZA (2 
mg/Kg) for at least 6 months. Response to AZA was observed in 9 out of the 16 patients.  
Apoptosis evaluation 
In initial experiments we evaluated the apoptosis induced by AZA, 6-MP and 6TG treatment on 
unstimulated and CD3/CD28 stimulated CD4+ T cells. As expected (11), unstimulated cells co-
incubated with the drugs showed level of apoptosis comparable to that observed in unstimulated 
untreated cells (data not shown), furthermore no difference was observed among AZA, 6-MP and 
6TG.  As opposite, AZA was able to increase the % of apoptotic cells observable in CD4+T cells 
stimulated with aCD3/28 mAb and the apoptosis induction by AZA, 6-MP and 6TG was 
comparable (data not shown).  
Fig. 1A shows the % of apoptosis observable in CD3/aCD28 stimulated T cells in the presence 
(treated cells) or absence (untreated) of AZA in CD patients according to the response to AZA.  The 
% of apoptosis in stimulated but untreated cells was not different between responder (R) patients 
and not responder patients (NR) (R: 20.2 (10.8-38.8); NR: 23.8 (8.1-58.3) median (range) p=0.60 
by Mann Whitney test). All the patients showed an increase in the % of apoptotic cells in the 
presence of AZA (p<0.05 by Wilcoxon test). However, CD3/28 stimulation   in the presence of 
AZA was associated with higher (albeit not statistically significant) % of apoptotic cells in 
responder patients when compared to non responders (R: 44.3 %( 23.6-89.1); NR: 35.6% (15.2-
96.1), median (range).p=0.25 by Mann Whitney test). Comparable results were obtained   with 
CD3/28 stimulation in the presence of   6-MP and 6TG (data not shown). 
To quantify the ability of AZA to increase the apoptosis observable after aCD3/aCD28 stimulation, 
we conveyed the data as apoptosis stimulation index. As shown in Fig. 1B NR patients showed a 
significant reduced apoptosis stimulation index when compared to R patients. In two NR patients 
apoptosis was evaluated after incubation of lymphocytes with AZA 10M also. In both cases the % 
of apoptosis observed was not different from the one observed in cultures containing AZA 5M 
(data not shown) 
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IFN-production:  
We next evaluated the amount of IFN- in the supernatants of cell cultures utilized for apoptosis 
evaluation. As shown in Fig. 1C and D, incubation with AZA reduced the IFN- production in R 
patients to a greater extent when compared to NR patients. Of interest, NR patients showed a 
significant increase of basal IFN- production by stimulated CD4+T cells when compared to R 
patients (NR: 209518 (2800 -2.1020e+006 ); R: 12668 (1700 -160076 ) pg/ml  median (range) 
p=0.04 by Mann Whitney test) .  
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DISCUSSION  
 
In the present study we describe the differential ability of AZA to induce apoptosis of aCD3/28 
stimulated peripheral blood CD4+T cells in patients with a previous response to AZA when 
compared to patients that did not respond to a previous AZA treatment. AZA induced a 
significantly higher degree of apoptosis in peripheral blood cells from patients with previous 
response to AZA, than in cells from patients who did not respond to a previous AZA treatment. The 
observed different apoptosis response to AZA was not related to a different % of apoptosis 
observable between the two groups of patients after aCD3/28 stimulation and, therefore it seems the 
expression of   an intrinsic   difference in the response to AZA.  
Factors that may influence the response to thiopurines include the thiopurine 
methyltransferase (TPMT) activity     which influences the   active 6-thioguanine nucleotides (6-
TGMP, 6-TGDP, and 6-TGTP) levels. TPMT activity shows wide interindividual differences 
because of common genetic polymorphisms. However a very high TPMT activity that is associated 
with pharmacologic resistance to AZA   has been described in 1% of IBD patients while around 
90%   present a normal TPMT activity (15). Moreover, we observed similar   differences in the 
induction of apoptosis between responders and non responders patients when CD4+T cells were 
stimulated in the presence of 6-TG which is less affected by TPMT (16). Therefore, it is unlikely 
that interindividual differences in TPMT activity might account for the difference in apoptosis 
observed in the present study. Factors like   disease activity and treatment at the time of blood 
collection might have   influenced the “in vitro” response to azathioprine observed in the present 
study. However, disease activity as well as treatment with AZA was comparable between the 
groups of responder and not responder patients at the time of blood sample collection. The majority 
of non responder patients were, in fact, treated with systemic or local steroids and/or infliximab. In 
spite of the known ability of steroids (17) and infliximab to induce apoptosis (18), we did not 
observe differences in the % of apoptotic peripheral CD4+T cells after aCD3/28 stimulation in the 
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group of non responder when compared to   responder patients. On the basis of this observation   it 
seems unlikely that treatment at the time of blood collection might have influenced the apoptotic 
response to AZA in our study.  
As a consequence of the differential apoptosis observed between responder and non 
responder patients, we observed a greater reduction of IFN- content in cultures from responder 
when compared to non responder patients. Interestingly,   a significant higher levels of IFN-was 
observed in CD4+T cells stimulated with aCD3/28 in   non responder patients  when compared to 
responders. Since no difference in the % of apoptosis was observed between non responders and 
responders upon stimulation with aCD3/28, this condition might specifically   influence   the 
apoptotic response to AZA. This observation, together with the observed significant increase of the 
disease duration in non responder patients, when compared to responders, suggests that the response 
to AZA might be influenced by qualitative/quantitative differences in the inflammatory milieu 
somehow associated with the duration of inflammation. Whether IFN- production might by itself 
influence the “in vitro” apoptotic response to AZA or represent a marker for different factors able to 
influence the apoptosis process remains to be investigated.    
In summary, we observed a differential “in vitro” thiopurine-apoptotic response of peripheral blood 
CD4+T cells isolated from CD patients responders or non responders to AZA. This feature seems to 
be independent from the time interval between AZA treatment and blood sampling and rather linked 
with an individual trait of the inflammation. Once confirmed in a large prospective study, present 
findings suggest that the evaluation of apoptosis stimulation index of peripheral CD4+T cell after 
incubation with AZA might represent a parameter useful for a proper selection of CD patients 
candidate to thiopurine treatment. 
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Table1.  Clinical Characteristics of Crohn’s Disease Patients.  
 
 
 
Responder 
Patients 
(n=9) 
Non responder 
Patients 
(n=7) 
p 
M/F 4/5 3/4  
Age (y) 
mean±SD 
range 
38±15 
16-65 
51±14 
33-71 
>0.05 
Disease duration (y) 
mean±SD 
range 
14±9 
3-27 
25±8 
12-36 
0.02 
Indication for AZA treatment    
Steroid-dependence 4 4  
Steroid dependence and fistula 
(perianal disease) 
5 (4) 3 
 
CD localization at the time of AZA treatment 
( post-surgical recurrent disease) 
   
Small bowel 5(3) 6(5)  
Small and large bowel 4 1  
CD localization and behavior at the time of 
blood collection 
   
Small bowel (recurrent disease) 5(3) 6(5)  
Small and large bowel (recurrent disease) 4 1  
Fistulae ( perianal disease )   2 (1*) 3  
CD activity at the time of blood collection    
Active (CDAI >150) 2 2  
Remission (CDAI 150) 7 5  
Treatment at the time of blood collection    
AZA 3 2  
5-ASA 8 6  
Prednisone  2  
Budesonide 2(1*;1§) 3  
Infliximab**  3  
Duration of AZA treatment at the time of  
blood collection 
(months) 14, 12, 42 11, 40 
 
AZA-free period at the time of blood 
collection  
(months) 
84*, 14§,41, 2, 
12,12 18, 3, 6, 5, 3 
 
* One steroid-dependent patient with perianal fistula showing AZA response with steroid-free remission and fistula 
closure, voluntary discontinued AZA and experienced  recurrence of perianal fistula and steroid-dependence.  
§ One steroid-dependent patient who voluntary discontinued AZA showed recurrence of steroid-dependence. 
** Maintenance treatment. 
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Fig. 1 
 
 
 
Figure legend 
Fig. 1. “In vitro”   effect of AZA on peripheral blood CD4+T lymphocytes in patients responder or 
non responder to AZA treatment (2 mg/Kg).  Cells were stimulated with aCD3/28 mAbs in the 
presence or in the absence of AZA (see methods). Panel A: % of apoptotic cells in cell culture of 
CD4+T cells in the absence or in the presence of  AZA (+AZA);  Panel B: apoptosis stimulation 
index. Panel C: IFN- production in cell culture of CD4+T cells in the absence or in the presence of  
AZA (+AZA). Panel D: IFN- stimulation index. R= responder patients, NR= non responder 
patients. 
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